Korsana (KRSA) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Based on 5 analyst targets
6 firms have rated Korsana Biosciences (KRSA) in the last 3 months: 6 buy, 0 hold and 0 sell. Their average 12-month price target is $51.20, 53.4% above a share price of $33.38, ranging from $43 (Stifel) to $70 (Guggenheim). No firm has changed its rating in that time.
Recent analyst ratings
Last 3 months| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Initiated Coverage | Overweight | $44.00 | Nov 13, 2026 |
| Wedbush | Initiated Coverage | Outperform | $44.00 | Oct 5, 2026 |
| Guggenheim | Initiated Coverage | Buy | $70.00 | Sep 28, 2026 |
| Stifel | Initiated Coverage | Buy | $43.00 | Sep 14, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Sep 14, 2026 |
| UBS | Initiated Coverage | Buy | $55.00 | Sep 11, 2026 |
Frequently asked questions
What is the price target for KRSA stock?
The average 12-month analyst price target for Korsana (KRSA) is $51.20, with a high estimate of $70.00 and a low of $43.00, across 5 analysts.
Is KRSA a buy, sell, or hold?
Analysts covering Korsana currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for KRSA?
The average price target of $51.20 implies 44.43% upside from the last price of $35.45.
Who has the highest and lowest price target for KRSA?
Among the price targets analysts have published for Korsana in the last 3 months, the highest is $70.00 from Guggenheim and the lowest is $43.00 from Stifel.
Has KRSA been upgraded or downgraded recently?
No. Korsana has had no analyst upgrades or downgrades in the last 3 months.
What is the latest analyst rating on KRSA?
On Nov 13, 2026, Wells Fargo initiated coverage of Korsana at Overweight with a price target of $44.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

